• Blog

    From Idea to Prescription: Bringing a Drug to Market

    Bringing a new drug to market is a complex and lengthy process that involves multiple phases of research, development, testing, and regulatory hurdles. Venture capital plays a critical role in each phase.

  • Blog

    Incubate Joins Bipartisan Chorus: March-In Proposal Is Bad Policy

    Read Incubate's blog on the recently announced March-In proposal.

  • Statement

    Incubate Submits Letter on HELP Committee Hearing

    Incubate is an international coalition of life science venture capitalists committed to educating policymakers on the role of venture capital in bringing promising, innovative treatments to patients in need.

  • Statement

    Life sciences investors applaud bipartisan bill to eliminate small-molecule penalty 

    This bipartisan legislation would eliminate the small-molecule penalty by aligning the price-setting timeline for small and large molecule medicines.

  • Blog

    2024 Open Letter on Life Sciences Policy

    An Open Letter to Members of Congress and the Biden Administration from Leaders in the Life Sciences Community As leaders...

  • Blog

    Incubate and DLA Piper Host Breakfast Panel at JPM24

    Incubate and DLA Piper hosted a breakfast panel at this year's J.P. Morgan Healthcare Conference in San Francisco, California.

  • Video

    Incubate Participates in Pulse Webinar

    Discussion on the vital role of M&A in bringing the next generation of biopharmaceutical breakthroughs to patients.

  • Statement

    Life sciences investors react to Biden administration’s march-in decision

    After a nine-month review, the Biden administration has reached the unprecedented and misguided conclusion that the 1980 Bayh-Dole Act gives it the authority to impose de facto price controls on drugs developed with federal research funding.

  • Event

    What is up for biopharmaceutical policy in 2024?

    Incubate and DLA Piper invite you to join us on the morning of Sunday, January 7th, as part of JPM Week 2024.

  • Blog

    Mary R. Grealy on the Small Molecule Penalty, U.S. Dominance in Life Sciences, and More

    Incubate Executive Director John Stanford sat down this week with Mary R. Grealy, CEO of the Healthcare Leadership Council, to discuss the latest developments in health policy on the Making Medicine podcast.

  • Statement

    Incubate releases statement on Fitch Ratings’ analysis of Medicare drug price negotiations

    Fitch Ratings recently released an analysis showing that Medicare's drug price negotiation program is expected to deter investments into small molecule drugs.